Who Generates More Revenue? Exelixis, Inc. or Xencor, Inc.

Exelixis leads in biotech revenue growth over Xencor.

__timestamp	Exelixis, Inc.	Xencor, Inc.
Wednesday, January 1, 2014	25111000	9520000
Thursday, January 1, 2015	37172000	27762000
Friday, January 1, 2016	191454000	87520000
Sunday, January 1, 2017	452477000	35711000
Monday, January 1, 2018	853826000	40603000
Tuesday, January 1, 2019	967775000	156700000
Wednesday, January 1, 2020	987538000	122694000
Friday, January 1, 2021	1434970000	275111000
Saturday, January 1, 2022	1611062000	164579000
Sunday, January 1, 2023	1830208000	168338000
Monday, January 1, 2024	2168701000

Infusing magic into the data realm

Revenue Race: Exelixis, Inc. vs. Xencor, Inc.

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, Exelixis, Inc. has consistently outperformed Xencor, Inc. in terms of revenue generation. Starting in 2014, Exelixis reported revenues of approximately $25 million, while Xencor lagged behind with just under $10 million. Fast forward to 2023, Exelixis has seen a remarkable increase, reaching nearly $1.83 billion, a staggering 7,200% growth. In contrast, Xencor's revenue grew to about $168 million, marking a more modest 1,665% increase. This data highlights Exelixis's strategic advancements and market positioning, making it a formidable player in the biotech sector. As both companies continue to innovate, the revenue gap remains a critical metric to watch.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025